R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation.

Date publication

mai 2022

Journal

JHEP reports : innovation in hepatology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BACHELLIER Philippe

Tous les auteurs :
Costentin C, Piñero F, Degroote H, Notarpaolo A, Boin IF, Boudjema K, Baccaro C, Podestá LG, Bachellier P, Ettorre GM, Poniachik J, Muscari F, Dibenedetto F, Duque SH, Salame E, Cillo U, Marciano S, Vanlemmens C, Fagiuoli S, Burra P, Van Vlierberghe H, Cherqui D, Lai Q, Silva M, Rubinstein F, Duvoux C,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35360522

Résumé

Patients with hepatocellular carcinoma (HCC) are selected for liver transplantation (LT) based on pre-LT imaging ± alpha-foetoprotein (AFP) level, but discrepancies between pre-LT tumour assessment and explant are frequent. Our aim was to design an explant-based recurrence risk reassessment score to refine prediction of recurrence after LT and provide a framework to guide post-LT management.

Mots clés

AFP, alpha-foetoprotein, Explants pathology, HBV, hepatitis B virus, HCC, hepatocellular carcinoma, HCV, hepatitis C virus, LT, liver transplantation, Liver cancer, Liver transplantation, MVI, microvascular invasion, Prediction, R3, recurrence risk reassessment, RETREAT, Risk Estimation of Tumour Recurrence After Transplant, Recurrence, SHR, sub-distribution of hazard ratio, TC, test cohort, TTR, time to recurrence, VC, validation cohort

Référence

JHEP Rep. 2022 May;4(5):100445